Vtv therapeutics inc. (VTVT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss before noncontrolling interest

-25,121

-21,938

-17,384

-13,385

-17,867

-23,845

-36,109

-46,503

-50,321

-54,647

-53,766

-54,916

-56,119

-55,353

-52,701

-49,019

-44,814

-41,107

0

0

0

Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Gain on disposal of property and equipment, net

-

-

-

-

-

12

12

28

28

11

0

0

0

-

-

-

-

-

-

-

-

Depreciation expense

58

39

131

153

184

218

156

174

187

197

201

221

238

265

356

402

447

501

0

0

0

Share-based compensation expense

1,617

1,518

1,426

1,592

1,994

2,676

3,333

3,713

3,869

3,645

3,310

3,033

2,773

2,641

0

0

0

-

-

-

-

Change in fair value of contingent distribution

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

695

0

0

0

Change in fair value of warrants, related party

457

-827

198

-267

-308

638

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

394

532

669

802

924

1,014

1,071

1,097

1,101

1,029

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense distribution payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

0

0

0

Bad debt (recovery) expense related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

0

0

0

Changes in assets and liabilities:
Accounts receivable

-

-

-

-

-

-8,000

0

0

0

-

-

-

-

-69

0

0

0

-

-

-

0

Prepaid expenses and other assets

140

-732

-999

-2,063

-2,274

1,135

1,192

1,723

1,732

-170

-333

216

-564

-502

259

266

1,089

1,020

0

0

0

Employee loans receivable – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-49

-46

-36

-36

-12

0

0

0

Receivable due from a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Long-term deposits

-

-

-

-

-

-2,256

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

Other long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

251

-

0

0

0

Accounts payable and accrued expenses

1,158

-618

-2,051

-4,807

-5,039

-6,199

-1,195

2,370

151

2,448

76

1,244

3,150

4,786

4,803

3,327

1,348

2,930

0

0

0

Accounts payable and accrued expenses – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-880

-110

31

1,466

2,458

0

0

0

Contract liabilities

-850

-1,755

-6,271

-9,638

-9,284

-10,435

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-93

-

0

0

0

-

-

-

-

Other liabilities

-

-

-

-

-

-32

-27

-17

-14

24

29

17

30

19

150

68

-92

-871

0

0

0

Net cash used in operating activities

-23,128

-23,018

-23,011

-23,076

-26,909

-26,856

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-49,523

-

-45,753

-42,847

-40,082

-36,946

0

0

0

Proceeds from sale of assets

-

-

-

-

-

12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

57

0

0

0

-

-

-

-

104

0

0

0

Net cash provided by (used in) investing activities

-

-

-

-

-

7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of Class A Common Stock to a related party under the Letter Agreements

27,500

27,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Class A Common Stock, net of offering costs

-

5,443

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-79

0

0

0

Proceeds from debt issuance

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Repayment of notes payable

9,667

10,573

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

18,333

22,870

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents

-4,553

94

-1,330

299

-1,576

-10,237

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from debt issuance related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19,289

0

0

0

Repayment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

123,644

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-30,351

-

-45,952

61,444

74,725

86,619

0

0

0

Non-cash activities:
Change in redemption value of noncontrolling interest

-16,598

13,405

-25,004

-4,108

64,538

52,873

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock

-

-

-

-

-

151

0

0

0

-

-

-

-

3,164

0

0

0

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred revenue included in accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Redeemable Noncontrolling Interest [Member]
Change in redemption value of noncontrolling interest

16,598

-13,405

25,004

4,108

-64,538

-52,873

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-